Business
METiS TechBio to Present Late-Breaking Data on Near-Complete Cardiomyocyte Delivery at CRS 2026
METiS TechBio (7666.HK), a global leader in AI-powered drug delivery innovation, today announced that new preclinical data from its heart-targeted LNP program has been selected for a Late-Breaking oral presentation at the 2026 Controlled Release Society (CRS) Annual Meeting. Dr. Andong Liu, Vice President and Head of Technology Platform at METiS TechBio, will deliver a Late-Breaking oral presentation at the 2026 CRS Annual Meeting in Lisbon, Portugal, this July. The presentation is titled "Syste
About this update from Metis Techbio Co., Ltd. Class H
[{"type":"text","content":"BEIJING, HANGZHOU, China and CAMBRIDGE, Mass., May 20, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a global leader in AI-powered drug delivery innovation, today announced that new preclinical data from its heart-targeted LNP program has been selected for a Late-Breaking oral presentation at the 2026 Controlled Release Society (CRS) Annual Meeting. Dr. Andong Liu, Vice President and Head of Technology Platform at METiS TechBio, will deliver a Late-Breaking oral presentation at the 2026 CRS Annual Meeting in Lisbon, Portugal, this July. The presentation is titled "Systemic Heart-Selective Lipid Nanoparticles for High-Efficiency In Vivo Delivery and Cardiomyocyte Gene Editing."","length":695,"tagName":"p"},{"type":"text","content":"In this study, leveraging its proprietary NanoForge AI nanodelivery platform, METiS TechBio achieved near-complete (~100%) cardiomyocyte transfection and significant gene editing following intravenous administration through AI-driven lipid discovery, formulation optimization, and active targeting ligand engineering. The selection of these findings for a Late-Breaking oral presentation at this year's CRS Annual Meeting represents a significant advance in extrahepatic LNP delivery, establishing a first-in-class precision delivery capability to cardiomyocytes.","length":572,"tagName":"p"},{"type":"text","content":"The heart has long been considered one of the most challenging organs for extrahepatic LNP delivery. Cardiomyocytes, due to their high density and low endocytic activity, are widely recognized in the industry as one of the most difficult cell types for efficient delivery. Achieving near-complete cardiomyocyte transfection means that, for the first time, genetic medicines may be able to reach cardiomyocytes via systemic administration with substantially improved precision and efficiency while reducing off-target risks. This opens up new therapeutic possibilities for major cardiovascular diseases and clinical needs, including hereditary cardiomyopathies, heart failure, and post-myocardial infarction repair. It also signals that AI-driven organ-targeted delivery technology is advancing from proof-of-concept toward potential clinical value.","length":853,"tagName":"p"},{"type":"text","content":""Extrahepatic delivery remains one of the most important challenges in geneti...